1 results match your criteria: "Rigshospitalet-Koebenhavn[Affiliation]"
Article Synopsis
- The PROLONG study analyzed the effectiveness of ofatumumab maintenance therapy in patients with relapsed chronic lymphocytic leukemia (CLL) who were in remission after prior treatments.
- Ofatumumab treatment resulted in a median progression-free survival of 34.2 months compared to 16.9 months for those in the observation group, highlighting a significant benefit (P < 0.0001).
- While the overall survival rates were similar between both groups, ofatumumab was associated with a higher incidence of grade 3 or higher adverse events, but it was generally well tolerated by patients.